Skip to main content
DuChemBio Co, LTD logo

DuChemBio Co, LTD — Investor Relations & Filings

Ticker · 176750 ISIN · KR7176750008 KO Manufacturing
Open in API
Filings indexed 291 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 176750

About DuChemBio Co, LTD

http://www.duchembio.com/en/

DuChemBio Co., Ltd. is a pharmaceutical company specializing in the development, manufacturing, and commercialization of radiopharmaceuticals. The company focuses on products for both diagnosis and treatment, with a primary emphasis on positron emission tomography (PET) imaging tracers. Its portfolio targets key therapeutic areas, including oncology for cancer detection and neurology for conditions such as Alzheimer's and Parkinson's disease. The company's mission is to develop novel radiopharmaceuticals and achieve successful commercialization on a global scale.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 92% confidence The document is titled “분기보고서 (제 24기) 2026년 01월 01일–2026년 03월 31일” which translates to a quarterly report covering Q1 2026. It includes detailed sections such as company overview, consolidated subsidiaries, credit ratings, share capital changes, financial results (revenue, operating profit increases), business content, and actual financial tables. The length (~206,000 characters) and substantive financial and narrative content confirm this is the full interim/quarterly report itself, not merely an announcement or appendix. Therefore, it fits the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-14 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 75% confidence The document is a correction filing (“정정신고”) concerning the grant of stock options (“주식매수선택권 부여에 관한 신고”). It outlines terms for issuance of new shares or delivery of treasury shares under the option plan. This is a corporate capital action (issuance of option-linked shares) rather than an earnings release, board change notice, or buyback. Therefore it falls under Share Issue/Capital Change (SHA).
2026-03-26 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 85% confidence The document is a formal notification filed with the Korean Financial Services Commission/KRX regarding the grant of stock purchase options (주식매수선택권 부여). It details option terms, exercise price, quantities, grant dates, and valuation assumptions. This constitutes an announcement of a contingent share issuance under the company’s equity compensation plan, i.e., a change in share capital structure rather than an earnings release, management change, or AGM material. Therefore, the correct category is Share Issue/Capital Change (SHA).
2026-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 94% confidence The document is the official Korean announcement of the Annual General Meeting (정기주주총회) results, including voting outcomes on resolutions, approval of financial statements, board member elections, and other AGM agenda items. This matches the ‘Declaration of Voting Results & Voting Rights Announcements’ category (DVA).
2026-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from DuchemBio. It provides a summary of the audit opinion, key financial data (assets, liabilities, equity, revenue, profit), and auditor information. While it contains financial data, it is a standard regulatory announcement of the audit report's submission rather than the full annual report (10-K) or a standalone audit report (AR). According to the 'Menu vs Meal' rule, this is an announcement of the report's availability, fitting the criteria for a Report Publication Announcement (RPA). FY 2025
2026-03-18 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for DuChemBio, covering the fiscal year ending December 31, 2025. It includes the independent auditor's report from Samjong KPMG, the consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. While it contains financial data, it is specifically the formal audit report required by regulatory standards, not a general annual report (10-K) or a simple earnings release. FY 2025
2026-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.